NEKTAR THERAPEUTICS - 8-K Filing
Nektar Therapeutics entered into an equity distribution agreement on May 8, 2026, allowing it to sell up to $150 million in common stock through Guggenheim Securities and H.C. Wainwright & Co., with a 3% commission fee per sale. Sandra Gardiner is retiring as interim CFO effective May 15, 2026, succeeded by Linda Rubinstein under an amended consulting agreement at $650/hour. (Items: 1.01 Entry Into a Material Definitive Agreement, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 9.01 Financial Statements and Exhibits)
Tickers: $NKTR